Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 176 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Anónimo. Gilenya (fingolimod): Drug Safety Communication - Severe worsening of multiple sclerosis after stopping the medicine. U.S. Food and Drug Administration 2018:20 de noviembre. [Ref.ID 102857]
2. Cita con resumen
Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]
3.Tiene citas relacionadas Cita con resumen
Gotzsche PC. Antidepressants are addictive and increase the risk of relapse. BMJ 2016;352:i574. [Ref.ID 100055]
4. Cita con resumen
Spielmans GI, Kirsch I. Drug approval and drug effectiveness. Annual Review of Clinical Psychology 2014;214:741-66. [Ref.ID 97582]
6. Cita con resumen
Anónimo. Long-acting injectable aripiprazole (Ablify Maintena) for schizophrenia. Med Lett Drugs Ther 2013;55:34-6. [Ref.ID 95657]
7. Cita con resumen
Smith RM, Tipple M, Chaudry MN, Schaefer MK, Park BJ. Relapse of fungal meningitis associated with contaminated methylprednisolone. N Engl J Med 2013;368:1. [Ref.ID 95554]
8.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
9.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
10.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
11.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
12.Tiene citas relacionadas
Ropper AH. The "poison chair" treatment for multiple sclerosis. N Engl J Med 2012;367:1149-50. [Ref.ID 93772]
13.Tiene citas relacionadas
Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, for the DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107. [Ref.ID 93770]
14.Tiene citas relacionadas Cita con resumen
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, for the CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. [Ref.ID 93769]
15.Tiene citas relacionadas Cita con resumen
Leucht S, Tardy M, Komosa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71. [Ref.ID 93128]
16. Cita con resumen
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, for the ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9. [Ref.ID 92520]
17. Cita con resumen
Anónimo. Lenalidomide (Revlimid): risk of secondary primary malignancy - update. Drug Safety Update 2011;5:1-2. [Ref.ID 91625]
18. Cita con resumen
Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y, on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155:409-14. [Ref.ID 91525]
19.Tiene citas relacionadas Cita con resumen
Chen EYH, Hui CLM, Lam MML, Chiu CPY, Law CW, Chung DWS, Tso S, Pang EPF, Chan KT, Wong YC, Mo FYM, Chan KPM, Yao TJ, Hung SF, Honer WG. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010;341:435. [Ref.ID 89258]
20.Tiene citas relacionadas
Craig JC, Webster AC, Loy C. How long should treatments be continued?. BMJ 2010;341:409-10. [Ref.ID 89252]
Seleccionar todas
 
 1 a 20 de 176 siguiente >>